Want to join the conversation?
$CELG's revenue from Revlimid grew 11.8% to $1.45Bil in 3Q15 from last year and Abraxane revenue rose 8.3% to $229.9MM. Pomalyst/Imnovid revenue jumped 41.6% to $256.5MM. Otezla revenue was $138.7MM in 3Q15, while Vidaza revenue fell 6.5% to $147.6MM and Thalomid revenue declined 13.1% to $45.1MM. Istodax revenue rose 10.2% to $17.3MM.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?